Cargando…
Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States
BACKGROUND: Recent attention to value frameworks has highlighted limitations of current conventional value and health technology assessment (V/HTA) methods (eg, cost-effectiveness). Multicriteria decision analysis (MCDA) has potential as a supplemental tool to incorporate additional value criteria i...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372975/ https://www.ncbi.nlm.nih.gov/pubmed/36125060 http://dx.doi.org/10.18553/jmcp.2022.28.10.1190 |
_version_ | 1785078465796505600 |
---|---|
author | Mendola, Nicholas D Oehrlein, Elisabeth Perfetto, Eleanor M Westrich, Kimberly McQueen, Robert Brett |
author_facet | Mendola, Nicholas D Oehrlein, Elisabeth Perfetto, Eleanor M Westrich, Kimberly McQueen, Robert Brett |
author_sort | Mendola, Nicholas D |
collection | PubMed |
description | BACKGROUND: Recent attention to value frameworks has highlighted limitations of current conventional value and health technology assessment (V/HTA) methods (eg, cost-effectiveness). Multicriteria decision analysis (MCDA) has potential as a supplemental tool to incorporate additional value criteria into conventional value assessment. OBJECTIVE: To conduct a pilot study to illustrate the impact of an MCDA approach on the value perceptions of hypothetical treatment profiles from a multistakeholder panel. METHODS: Participants voted on value perceptions of 2 hypothetical treatments with similar cost-effectiveness evidence: Treatment A for aggressive B-cell non-Hodgkin lymphoma in adults and treatment B for episodic migraine in adults. Participants voted treatments A and B as low, intermediate, or high value before and after a weighting exercise on prespecified, additional value criteria. Weights from participants were used to calculate treatment-specific MCDA scores from 0 (least favorable) to 100 (most favorable) and were presented to participants for a second value-perception vote. Analyses compared changes in value perceptions within treatments A and B post-MCDA exercise. RESULTS: Before considering MCDA scores for treatment A, 0% of participants considered it to be low, 52% intermediate, and 48% high value. After considering MCDA scores for treatment A, 4% considered it low, 29% intermediate, and 67% high value. Both before and after considering MCDA scores for treatment B, 13%, considered it low, 57% intermediate, and 30% high value. Mean MCDA scores for treatments A and B were 67 and 63, respectively. Of all stakeholders, 41% altered their perception of value for treatment A (9% negatively and 32% positively) and, separately, 45% for treatment B (23% both negatively and positively) after considering MCDA scores. CONCLUSIONS: With nearly half of participants altering their perception of value after consideration of additional value criteria, findings support the need for a more inclusive and flexible value assessment process. |
format | Online Article Text |
id | pubmed-10372975 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Academy of Managed Care Pharmacy |
record_format | MEDLINE/PubMed |
spelling | pubmed-103729752023-07-31 Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States Mendola, Nicholas D Oehrlein, Elisabeth Perfetto, Eleanor M Westrich, Kimberly McQueen, Robert Brett J Manag Care Spec Pharm Research Brief BACKGROUND: Recent attention to value frameworks has highlighted limitations of current conventional value and health technology assessment (V/HTA) methods (eg, cost-effectiveness). Multicriteria decision analysis (MCDA) has potential as a supplemental tool to incorporate additional value criteria into conventional value assessment. OBJECTIVE: To conduct a pilot study to illustrate the impact of an MCDA approach on the value perceptions of hypothetical treatment profiles from a multistakeholder panel. METHODS: Participants voted on value perceptions of 2 hypothetical treatments with similar cost-effectiveness evidence: Treatment A for aggressive B-cell non-Hodgkin lymphoma in adults and treatment B for episodic migraine in adults. Participants voted treatments A and B as low, intermediate, or high value before and after a weighting exercise on prespecified, additional value criteria. Weights from participants were used to calculate treatment-specific MCDA scores from 0 (least favorable) to 100 (most favorable) and were presented to participants for a second value-perception vote. Analyses compared changes in value perceptions within treatments A and B post-MCDA exercise. RESULTS: Before considering MCDA scores for treatment A, 0% of participants considered it to be low, 52% intermediate, and 48% high value. After considering MCDA scores for treatment A, 4% considered it low, 29% intermediate, and 67% high value. Both before and after considering MCDA scores for treatment B, 13%, considered it low, 57% intermediate, and 30% high value. Mean MCDA scores for treatments A and B were 67 and 63, respectively. Of all stakeholders, 41% altered their perception of value for treatment A (9% negatively and 32% positively) and, separately, 45% for treatment B (23% both negatively and positively) after considering MCDA scores. CONCLUSIONS: With nearly half of participants altering their perception of value after consideration of additional value criteria, findings support the need for a more inclusive and flexible value assessment process. Academy of Managed Care Pharmacy 2022-10 /pmc/articles/PMC10372975/ /pubmed/36125060 http://dx.doi.org/10.18553/jmcp.2022.28.10.1190 Text en Copyright © 2022, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Brief Mendola, Nicholas D Oehrlein, Elisabeth Perfetto, Eleanor M Westrich, Kimberly McQueen, Robert Brett Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States |
title | Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States |
title_full | Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States |
title_fullStr | Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States |
title_full_unstemmed | Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States |
title_short | Stakeholder perception of pharmaceutical value: A multicriteria decision analysis pilot case study for value assessment in the United States |
title_sort | stakeholder perception of pharmaceutical value: a multicriteria decision analysis pilot case study for value assessment in the united states |
topic | Research Brief |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372975/ https://www.ncbi.nlm.nih.gov/pubmed/36125060 http://dx.doi.org/10.18553/jmcp.2022.28.10.1190 |
work_keys_str_mv | AT mendolanicholasd stakeholderperceptionofpharmaceuticalvalueamulticriteriadecisionanalysispilotcasestudyforvalueassessmentintheunitedstates AT oehrleinelisabeth stakeholderperceptionofpharmaceuticalvalueamulticriteriadecisionanalysispilotcasestudyforvalueassessmentintheunitedstates AT perfettoeleanorm stakeholderperceptionofpharmaceuticalvalueamulticriteriadecisionanalysispilotcasestudyforvalueassessmentintheunitedstates AT westrichkimberly stakeholderperceptionofpharmaceuticalvalueamulticriteriadecisionanalysispilotcasestudyforvalueassessmentintheunitedstates AT mcqueenrobertbrett stakeholderperceptionofpharmaceuticalvalueamulticriteriadecisionanalysispilotcasestudyforvalueassessmentintheunitedstates |